Base de datos : MEDLINE
Búsqueda : Hiperprolactinemia [Palabras]
Referencias encontradas : 3010 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 301 va a la página                         

  1 / 3010 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:27776952
[Au] Autor:Ivanova SA; Osmanova DZ; Boiko AS; Pozhidaev IV; Freidin MB; Fedorenko OY; Semke AV; Bokhan NA; Kornetova EG; Rakhmazova LD; Wilffert B; Loonen AJ
[Ad] Dirección:Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation; National Research Tomsk Polytechnic University, Tomsk, Russian Federation.
[Ti] Título:Prolactin gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics.
[So] Fuente:Schizophr Res;182:110-114, 2017 04.
[Is] ISSN:1573-2509
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Antipsychotic drugs can cause hyperprolactinemia. However, hyperprolactinemia was also observed in treatment-naive patients with a first schizophrenic episode. This phenomenon might be related to the role of prolactin as a cytokine in autoimmune diseases. Extrapituitary prolactin production is regulated by an alternative promoter, which contains the functional single nucleotide polymorphism -1149 G/T (rs1341239). We examined whether this polymorphism was associated with hyperprolactinemia in patients with schizophrenia. METHOD: We recruited 443 patients with schizophrenia and 126 healthy controls. The functional polymorphism -1149 G/T (rs1341239) in the prolactin gene was genotyped with multiplexed primer extension, combined with MALDI-TOF mass spectrometry. Genotype and allele frequencies were compared between groups with the χ test and logistic regression models adjusting for covariates. RESULTS: The frequency of genotypes and alleles in patients with schizophrenia did not differ from those in control subjects. A comparison between patients with schizophrenia with and without hyperprolactinemia revealed significantly higher frequency of the G allele in patients with hyperprolactinemia than in patients without it (χ =7.25; p=0.007; OR=1.44 [1.10-1.89]). Accordingly, patients with hyperprolactinemia carried the GG genotype more frequently than patients without hyperprolactinemia (χ =9.49; p=0.009). This association remained significant after adjusting the estimates for such covariates as sex, age, duration of the diseases and the dose of chlorpromazine equivalents. CONCLUSION: This study revealed a significant association between the polymorphic variant rs1341239 and the development of hyperprolactinemia in patients with schizophrenia. The serum prolactin concentration in patients with schizophrenia treated with antipsychotics may provide an indication of the activity of the gene that regulates extrapituitary prolactin production which is believed to play a role in the immune system.
[Mh] Términos MeSH primario: Antipsicóticos/efectos adversos
Hiperprolactinemia/inducido químicamente
Hiperprolactinemia/genética
Polimorfismo de Nucleótido Simple/genética
Prolactina/genética
Esquizofrenia/tratamiento farmacológico
[Mh] Términos MeSH secundario: Adolescente
Adulto
Anciano
Femenino
Frecuencia de los Genes
Estudios de Asociación Genética
Genotipo
Seres Humanos
Masculino
Mediana Edad
Prolactina/sangre
Esquizofrenia/sangre
Esquizofrenia/genética
Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción
Estadísticas no Paramétricas
Adulto Joven
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Antipsychotic Agents); 9002-62-4 (Prolactin)
[Em] Mes de ingreso:1801
[Cu] Fecha actualización por clase:180113
[Lr] Fecha última revisión:180113
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:161026
[St] Status:MEDLINE


  2 / 3010 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29187947
[Au] Autor:Taieb A; Maha KN; El Abed YH; Beizig AM; Chadli MC; Ach K
[Ad] Dirección:Endocrinology and Diabetes Department, University Hospital Farhat Hached Sousse, Tunisia.
[Ti] Título:Macroprolactinemia and Empty Sella Syndrome.
[So] Fuente:Pan Afr Med J;27:278, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicación:Uganda
[La] Idioma:eng
[Ab] Resumen:Macroprolactinemia is a polymeric form of prolactin-release, causing mildly symptomatic clinical pictures. The former can be isolated or associated with other causes of hyperprolactinemia. The association with an empty sella syndrome is rare. We report a case of a female patient discovered with this association. It's about a female patient 47 years old, followed up since the age of 31 years for bilateral galactorrhea and a spaniomenorrhea. There has been no associated drug intake. Her exploration has showed a serum prolactin level of 635 mIU/L. Thyroid test results were normal T4 = 10,2ng/L and TSH = 1.76 mIU/L. A brain scan has showed an empty sella turcica. Despite the unchanged levels of prolactinemia, the evolution under dopaminergic 5 mg /D has been marked by the occurrence of a pregnancy with persistent moderate hyperprolactinemia in the postpartum. Chromatography has showed a predominance of the macroprolactin form with: Prolactin monomer at 4.8%, Big Prolactin at 5% and Big Big Prolactin at 83%, thus stopping bromocriptine. Our observation suggests that macroprolactinemia can be associated with conventional etiologies of moderate hyperprolactinemia as the empty sella syndrome. Its detection would prevent the use of dopaminergic therapy which seems not useful.
[Mh] Términos MeSH primario: Síndrome de Silla Turca Vacía/diagnóstico
Hiperprolactinemia/etiología
Prolactina/sangre
[Mh] Términos MeSH secundario: Bromocriptina/administración & dosificación
Agonistas de Dopamina/administración & dosificación
Síndrome de Silla Turca Vacía/complicaciones
Femenino
Seres Humanos
Mediana Edad
[Pt] Tipo de publicación:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Dopamine Agonists); 0 (prolactin, polymeric); 3A64E3G5ZO (Bromocriptine); 9002-62-4 (Prolactin)
[Em] Mes de ingreso:1712
[Cu] Fecha actualización por clase:171219
[Lr] Fecha última revisión:171219
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:171201
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.2017.27.278.11361


  3 / 3010 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28904704
[Au] Autor:Barka I; Dendana E; Chikhrouhou N; Maroufi A; Kacem M; Chadli M; Ach K
[Ad] Dirección:Service d'Endocrinologie, CHU Farhat Hached de Sousse, Tunisie.
[Ti] Título:[Prolactin-secreting microadenoma in menopausal women].
[Ti] Título:Micro adénome à prolactine à l'âge de la ménopause..
[So] Fuente:Pan Afr Med J;27:177, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicación:Uganda
[La] Idioma:fre
[Ab] Resumen:Prolactin-secreting adenoma is rare in elderly women. Patient's clinical picture may be confused with that of menopause, making diagnosis sometimes difficult. We report the case of a 57-year old woman with a 2-year history of secondary amenorrhea without hot flushes associated with galactorrhea in order to highlight the peculiarities of prolactin-secreting microadenomas. Physical examination confirmed the diagnosis of galactorrhoea and biology showed hyperprolactinemia at mIU/L, FSH = 15.1 IU/L and LH = 4,1 IU/L. Pituitary MRI showed left adenoma measuring 8 mm. Patient's evolution under dopaminergic treatment was marked by the recovery, for a transitional period, of mestrual cycles and the occurrence of hot flushes, normalization of prolactin levels and reduction of adenoma size.
[Mh] Términos MeSH primario: Adenoma/diagnóstico por imagen
Neoplasias Hipofisarias/diagnóstico por imagen
Prolactina/secreción
Prolactinoma/diagnóstico por imagen
[Mh] Términos MeSH secundario: Adenoma/patología
Adenoma/terapia
Amenorrea/diagnóstico
Amenorrea/etiología
Femenino
Galactorrea/diagnóstico
Galactorrea/etiología
Seres Humanos
Hiperprolactinemia/etiología
Imagen por Resonancia Magnética
Menopausia
Mediana Edad
Neoplasias Hipofisarias/patología
Neoplasias Hipofisarias/terapia
Prolactinoma/patología
Prolactinoma/terapia
[Pt] Tipo de publicación:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nombre de substancia:
9002-62-4 (Prolactin)
[Em] Mes de ingreso:1709
[Cu] Fecha actualización por clase:170925
[Lr] Fecha última revisión:170925
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170915
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.2017.27.177.11677


  4 / 3010 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28780516
[Au] Autor:Chiloiro S; Giampietro A; Bianchi A; Tartaglione T; Capobianco A; Anile C; De Marinis L
[Ad] Dirección:Pituitary UnitDepartment of Endocrinology.
[Ti] Título:DIAGNOSIS OF ENDOCRINE DISEASE: Primary empty sella: a comprehensive review.
[So] Fuente:Eur J Endocrinol;177(6):R275-R285, 2017 Dec.
[Is] ISSN:1479-683X
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:Primary empty sella (PES) is characterized by the herniation of the subarachnoid space within the sella, which is often associated with variable degrees of flattening of the pituitary gland in patients without previous pituitary pathologies. PES pathogenetic mechanisms are not well known but seem to be due to a sellar diaphragm incompetence, associated to the occurrence of upper sellar or pituitary factors, as intracranial hypertension and change of pituitary volume. As PES represents in a majority of cases, a neuroradiological findings without any clinical implication, the occurrence of endocrine, neurological and opthalmological symptoms, due to the above describes anatomical alteration, which delineates from the so called PES syndrome. Headache, irregular menses, overweight/obesity and visual disturbances compose the typical picture of PES syndrome and can be the manifestation of an intracranial hypertension, often associated with PES. Although hyperprolactinemia and growth hormone deficit represent the most common endocrine abnormalities, PES syndrome is characterized by heterogeneity both in clinical manifestation and hormonal alterations and can sometime reach severe extremes, as occurrence of papilledema, cerebrospinal fluid rhinorrhea and worsening of visual acuity. Consequently, a multidisciplinary approach, with the integration of endocrine, neurologic and ophthalmologic expertise, is strongly advocated and recommended for a properly diagnosis, management, treatment and follow-up of PES syndrome and all of the related abnormalities.
[Mh] Términos MeSH primario: Enfermedades Asintomáticas
Síndrome de Silla Turca Vacía/diagnóstico
Encefalocele/diagnóstico
Hipófisis/diagnóstico por imagen
Silla Turca/diagnóstico por imagen
Espacio Subaracnoideo/diagnóstico por imagen
[Mh] Términos MeSH secundario: Síndrome de Silla Turca Vacía/diagnóstico por imagen
Síndrome de Silla Turca Vacía/fisiopatología
Síndrome de Silla Turca Vacía/terapia
Encefalocele/diagnóstico por imagen
Encefalocele/fisiopatología
Encefalocele/terapia
Hormona de Crecimiento Humana/deficiencia
Hormona de Crecimiento Humana/secreción
Seres Humanos
Hiperprolactinemia/etiología
Hiperprolactinemia/prevención & control
Hipertensión Intracraneal/etiología
Hipertensión Intracraneal/prevención & control
Imagen por Resonancia Magnética
Neuroimagen
Papiledema/etiología
Papiledema/prevención & control
Hipófisis/fisiopatología
Hipófisis/secreción
Silla Turca/fisiopatología
Índice de Severidad de la Enfermedad
Espacio Subaracnoideo/fisiopatología
[Pt] Tipo de publicación:JOURNAL ARTICLE; REVIEW
[Nm] Nombre de substancia:
12629-01-5 (Human Growth Hormone)
[Em] Mes de ingreso:1710
[Cu] Fecha actualización por clase:171020
[Lr] Fecha última revisión:171020
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170807
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0505


  5 / 3010 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28763467
[Au] Autor:Wang ZL; Yang LY; Chen HH; Lin HH; Tsai YT; Huang WJ
[Ad] Dirección:Department of Physiology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
[Ti] Título:Effects of TNF-α on penile structure alteration in rats with hyperprolactinemia.
[So] Fuente:PLoS One;12(8):e0181952, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:This study aimed to investigate the effects of anti-tumor necrosis factor (TNF)-α antibody (Ab) on alteration of penile structure in the hyperprolactinemia (hyperPRL) rat model. HyperPRL was induced in 8-week-old male Sprague-Dawley rats by allografting anterior pituitary (AP) glands under the renal capsule (+AP rats). Rats implanted with cerebral cortex (CX) were used as sham control (+CX rats). At 6 weeks post implantation, rats received either a single intra-testicular dose of TNF-α Ab (12.5 µg/kg) or testosterone replacement (2 doses of testosterone enanthate [TE], 3 mg/kg), and they were sacrificed 1 week later. Blood and penile tissue was collected for analysis. Compared to +CX rats, the +AP group had lower serum testosterone concentration and neuronal nitric oxide synthase (nNOS) expression, but exhibited a higher ratio of collagen III/I in the corpus cavernosum. Smooth muscle content exhibited no significant changes. At 1 week post TNF-α Ab injection, the collagen III/I ratio in the +AP group was decreased, and the smooth muscle content and nNOS expression increased significantly. These findings were comparable to those observed in +AP rats receiving TE. Testicular TNF-α suppresses testosterone release, which in turn results in the erectile dysfunction (ED) seen in hyperPRL. Intra-testicular TNF-α Ab treatment is as effective as testosterone supplementation on penile structure normalization in the hyperPRL model.
[Mh] Términos MeSH primario: Anticuerpos/farmacología
Hiperprolactinemia/sangre
Pene/patología
Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
[Mh] Términos MeSH secundario: Animales
Corteza Cerebral/metabolismo
Colágeno/química
Disfunción Eréctil/fisiopatología
Macrófagos/metabolismo
Masculino
Músculo Liso/metabolismo
Óxido Nítrico Sintasa de Tipo I/metabolismo
Erección Peniana
Prolactina/sangre
Prolactina/metabolismo
Ratas
Ratas Sprague-Dawley
Testosterona/sangre
Testosterona/metabolismo
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Antibodies); 0 (Tumor Necrosis Factor-alpha); 3XMK78S47O (Testosterone); 9002-62-4 (Prolactin); 9007-34-5 (Collagen); EC 1.14.13.39 (Nitric Oxide Synthase Type I); EC 1.14.13.39 (Nos1 protein, rat)
[Em] Mes de ingreso:1710
[Cu] Fecha actualización por clase:171017
[Lr] Fecha última revisión:171017
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170802
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181952


  6 / 3010 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28583458
[Au] Autor:Lin W; Gao L; Guo X; Wang W; Xing B
[Ad] Dirección:Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, People's Republic of China; Peking Union Medical College, Beijing, People's Republic of China.
[Ti] Título:Xanthomatous Hypophysitis Presenting with Diabetes Insipidus Completely Cured Through Transsphenoidal Surgery: Case Report and Literature Review.
[So] Fuente:World Neurosurg;104:1051.e7-1051.e13, 2017 Aug.
[Is] ISSN:1878-8769
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Xanthomatous hypophysitis (XH) is extremely rare. Only 27 cases have been reported in the literature. No XH patient presenting with diabetes insipidus (DI) has been completely cured through surgery. Here, we describe the first XH case of a DI patient whose pituitary function was normalized postoperatively, without hormone replacement therapy. CASE DESCRIPTION: A 41-year-old woman suffered from polydipsia, DI, headache, and breast discharge. Laboratory investigation revealed hyperprolactinemia. Pituitary magnetic resonance imaging showed a 2.0-cm × 1.4-cm × 1.6-cm lesion that demonstrated heterogeneous intensity on T1-weighted imaging and peripheral ring enhancement following contrast; the lesion was totally removed through transsphenoidal surgery. Histopathologic and immunohistochemical examinations confirmed the diagnosis of XH. At the 4- and 15-month follow-up visits, all pituitary-related hormones were normal, and the patient was not taking medication. A repeat pituitary magnetic resonance imaging showed no evidence of recurrence. CONCLUSIONS: To the best of our knowledge, this case is the first documented occurrence of XH with DI completely cured through surgery. If XH is suspected, total surgical resection of the lesion is recommended and normal pituitary tissue should be carefully protected intraoperatively.
[Mh] Términos MeSH primario: Diabetes Insípida/cirugía
Hiperprolactinemia/cirugía
Hipofisitis/cirugía
Xantomatosis/cirugía
[Mh] Términos MeSH secundario: Adulto
Diabetes Insípida/etiología
Femenino
Seres Humanos
Hiperprolactinemia/etiología
Hipofisitis/complicaciones
Hipofisitis/diagnóstico por imagen
Imagen por Resonancia Magnética
Neuroendoscopía
Xantomatosis/complicaciones
Xantomatosis/diagnóstico por imagen
[Pt] Tipo de publicación:CASE REPORTS; JOURNAL ARTICLE
[Em] Mes de ingreso:1709
[Cu] Fecha actualización por clase:170925
[Lr] Fecha última revisión:170925
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170607
[St] Status:MEDLINE


  7 / 3010 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28433845
[Au] Autor:Park HR; Kshettry VR; Farrell CJ; Lee JM; Kim YH; Won TB; Han DH; Do H; Nyguist G; Rosen M; Kim DG; Evans JJ; Paek SH
[Ad] Dirección:Department of Neurosurgery, Soonchunhyang University Seoul Hospital, Seoul, Korea; Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea.
[Ti] Título:Clinical Outcome After Extended Endoscopic Endonasal Resection of Craniopharyngiomas: Two-Institution Experience.
[So] Fuente:World Neurosurg;103:465-474, 2017 Jul.
[Is] ISSN:1878-8769
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: The extended endoscopic endonasal approach (EEA) to the anterior cranial base is used for the resection of craniopharyngiomas. OBJECTIVE: We present clinical experience and outcomes of using EEA for craniopharyngiomas. METHODS: A total of 116 patients in 2 remote institutions were enrolled in this retrospective study. Surgical, endocrinologic, and ophthalmologic outcomes were assessed. RESULTS: The mean follow-up was 35 months (range, 1-115). Gross total resection (GTR), near total resection (NTR, >95%), and subtotal resection (STR) were achieved in 46%, 39%, and 15% of the patients, respectively. Surgery performed after 2010 was the only variable significantly associated with greater extent of resection, which might be explained by the learning curve. Overall tumor recurrence rate was 15.5%, with a median interval until recurrence of 14.5 months (range, 3-58). Extent of resection was significantly associated with recurrence-free survival (P = 0.0116). Those who underwent NTR/STR followed by adjuvant radiotherapy had a similar median recurrence-free survival rate compared with those who underwent GTR (26.5 vs. 20 months, P = 0.167). Endocrinologic examination revealed that 47.4% of patients experienced worsening of anterior pituitary function following surgery while 25.5% developed new-onset diabetes insipidus. Of the 89 patients with preoperative visual deficits, 68 (76.4%) experienced improvement in visual field assessment. CONCLUSION: EEA is effective for the surgical resection of craniopharyngiomas, resulting in high rates of visual improvement and low complication rates. Adjuvant radiotherapy is a useful method for tumor control after incomplete resection.
[Mh] Términos MeSH primario: Craneofaringioma/cirugía
Neuroendoscopía/métodos
Neoplasias Hipofisarias/cirugía
[Mh] Términos MeSH secundario: Adolescente
Adulto
Anciano
Craneofaringioma/complicaciones
Craneofaringioma/fisiopatología
Diabetes Insípida/epidemiología
Diabetes Insípida/etiología
Supervivencia sin Enfermedad
Femenino
Seres Humanos
Hiperprolactinemia/etiología
Hipopituitarismo/epidemiología
Hipopituitarismo/etiología
Masculino
Mediana Edad
Cirugía Endoscópica por Orificios Naturales
Neoplasia Residual
Procedimientos Neuroquirúrgicos
Irradiación Hipofisaria
Neoplasias Hipofisarias/fisiopatología
Complicaciones Posoperatorias/epidemiología
Radioterapia Ayuvante
Estudios Retrospectivos
Resultado del Tratamiento
Trastornos de la Visión/etiología
Campos Visuales
Adulto Joven
[Pt] Tipo de publicación:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mes de ingreso:1709
[Cu] Fecha actualización por clase:170925
[Lr] Fecha última revisión:170925
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170424
[St] Status:MEDLINE


  8 / 3010 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28407622
[Au] Autor:Caponnetto S; Iannantuono GM; Barchiesi G; Magri V; Gelibter A; Cortesi E
[Ad] Dirección:Division of Medical Oncology, Department of Radiological, Oncological, and Pathological Sciences, "Sapienza" University of Rome, Rome, Italy.
[Ti] Título:Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
[So] Fuente:Oncology;93(1):62-66, 2017.
[Is] ISSN:1423-0232
[Cp] País de publicación:Switzerland
[La] Idioma:eng
[Ab] Resumen:BACKGROUND/AIMS: Prolactin (PRL) is a peptide hormone and several studies have demonstrated its role as a cytokine in human T cell-mediated immunity. We are unaware if PRL is a positive or negative immunomodulator, but its effects on the regulation of T cells could inhibit the antitumor activity elicited by nivolumab (NIVO). We aimed to assess whether the occurrence of hyperprolactinemia in metastatic non-small cell lung cancer (mNSCLC) patients treated with NIVO is associated with poor clinical outcomes. METHODS: We evaluated 26 mNSCLC patients treated with NIVO. Blood samples were collected in every patient to evaluate PRL basal levels before starting the therapy with NIVO and before each following administration of NIVO. All patients underwent a conventional CT to investigate the effect of therapy according to Immune-related Response Evaluation Criteria in Solid Tumors (IrRECIST). RESULTS: Twenty patients (77%) developed hyperprolactinemia during the treatment, whereas 6 patients (23%) had stable levels of PRL during the therapy (p = 0.001). A total of 95% of the 20 patients with hyperprolactinemia had progressive disease (PD), according to CT results, whereas only 2 patients (33%) out of 6 with stable PRL levels had PD (p = 0.004). CONCLUSIONS: Hyperprolactinemia in mNSCLC patients treated with NIVO could potentially represent a negative early predictive factor for poor clinical outcomes, thus anticipating PD shown by CT scan.
[Mh] Términos MeSH primario: Anticuerpos Monoclonales/uso terapéutico
Antineoplásicos/uso terapéutico
Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico
Hiperprolactinemia/sangre
Neoplasias Pulmonares/tratamiento farmacológico
Prolactina/sangre
[Mh] Términos MeSH secundario: Anciano
Anticuerpos Monoclonales/administración & dosificación
Anticuerpos Monoclonales/efectos adversos
Antineoplásicos/administración & dosificación
Antineoplásicos/efectos adversos
Biomarcadores de Tumor/sangre
Carcinoma de Pulmón de Células no Pequeñas/sangre
Carcinoma de Pulmón de Células no Pequeñas/inmunología
Carcinoma de Pulmón de Células no Pequeñas/patología
Femenino
Seres Humanos
Hiperprolactinemia/etiología
Neoplasias Pulmonares/sangre
Neoplasias Pulmonares/inmunología
Neoplasias Pulmonares/patología
Masculino
Mediana Edad
Valor Predictivo de las Pruebas
Prolactina/secreción
Resultado del Tratamiento
[Pt] Tipo de publicación:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nombre de substancia:
0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 31YO63LBSN (nivolumab); 9002-62-4 (Prolactin)
[Em] Mes de ingreso:1710
[Cu] Fecha actualización por clase:171018
[Lr] Fecha última revisión:171018
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170414
[St] Status:MEDLINE
[do] DOI:10.1159/000464328


  9 / 3010 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28320371
[Au] Autor:Omi T; Ito H; Riku K; Kanai K; Takada H; Fujimi S; Matsunaga H; Ohi K
[Ad] Dirección:Department of Psychiatry, Osaka General Medical Center, Osaka, Japan. omi@gh.opho.jp.
[Ti] Título:Possible factors influencing the duration of hospital stay in patients with psychiatric disorders attempting suicide by jumping.
[So] Fuente:BMC Psychiatry;17(1):99, 2017 Mar 20.
[Is] ISSN:1471-244X
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Patients with psychiatric disorders have a high rate of suicide. The present study investigated factors influencing hospital stays for Japanese patients with psychiatric disorders attempting suicide by jumping. METHODS: We diagnosed all suicide attempts (n = 113) by jumping based on the International Classification of Diseases 10th Revision (ICD-10) and investigated the mean hospital stays of patients with each diagnosis based on the ICD-10 code. We then analyzed differences in the demographic and clinical characteristics between the diagnostic groups to identify factors influencing the duration of hospital stay. RESULTS: Patients diagnosed with schizophrenia (F2 code) were the most frequent (32.7%) of all diagnoses; therefore, we divided the diagnostic groups into schizophrenia group (n = 37) and other psychiatric diagnoses group (n = 76). The patients with schizophrenia showed a significantly longer hospital stay (125.7 ± 63.9 days) compared with the patients with other psychiatric diagnoses (83.6 ± 63.2) (ß ± SE = 42.1 ± 12.7, p = 0.0013), whereas there was no difference in the jump height between the two groups (the average was the 3rd to 4th floor; p > 0.05). The number of injured parts, particularly lower-limb fractures, was significantly higher (p = 0.017) in patients with schizophrenia than in patients with other psychiatric diagnoses. The duration of psychiatric treatment in patients with schizophrenia were significantly longer (z = 3.4, p = 0.001) than in patients with other psychiatric diagnoses. CONCLUSION: Our findings indicate that the number of injuries and the body parts injured in patients with schizophrenia are associated with a longer duration of hospital stay following a suicide attempt by jumping. The current use of antipsychotics and a longer duration of taking antipsychotics might contribute to the risk of bone fracture via hyperprolactinemia. Further cognitive impairment in patients with schizophrenia might prevent rehabilitation for the management of lower-limb fractures. From these results, we suggest that clinicians should monitor the level of prolactin and cognitive function in patients with schizophrenia in future studies on managing of lower-limb fractures.
[Mh] Términos MeSH primario: Tiempo de Internación/estadística & datos numéricos
Trastornos Mentales/epidemiología
Trastornos Mentales/psicología
Esquizofrenia/epidemiología
Psicología del Esquizofrénico
Intento de Suicidio/psicología
Intento de Suicidio/estadística & datos numéricos
[Mh] Términos MeSH secundario: Adulto
Antipsicóticos/efectos adversos
Antipsicóticos/uso terapéutico
Femenino
Fracturas Óseas/inducido químicamente
Seres Humanos
Hiperprolactinemia/inducido químicamente
Japón
Traumatismos de la Pierna/inducido químicamente
Masculino
Trastornos Mentales/tratamiento farmacológico
Mediana Edad
Estudios Retrospectivos
Factores de Riesgo
Esquizofrenia/tratamiento farmacológico
Heridas y Lesiones/epidemiología
Heridas y Lesiones/psicología
Adulto Joven
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Antipsychotic Agents)
[Em] Mes de ingreso:1708
[Cu] Fecha actualización por clase:170817
[Lr] Fecha última revisión:170817
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170322
[St] Status:MEDLINE
[do] DOI:10.1186/s12888-017-1267-5


  10 / 3010 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28320278
[Au] Autor:Kurina AU; Pronina TS; Dilmukhametova LK; Maleev GV; Ugrumov MV
[Ad] Dirección:Koltzov Institute of Developmental Biology, Russian Academy of Sciences, Moscow, 119334, Russia. kurina.anya@gmail.com.
[Ti] Título:Cooperative Synthesis of Dopamine in Rat Mediobasal Hypothalamus as a Compensatory Mechanism in Hyperprolactinemia.
[So] Fuente:Biochemistry (Mosc);82(3):366-372, 2017 Mar.
[Is] ISSN:1608-3040
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Dopamine (DA), synthesized in the mediobasal hypothalamus by dopaminergic neurons containing two enzymes of DA synthesis - tyrosine hydroxylase and decarboxylase of aromatic L-amino acids, or by monoenzymatic non-dopaminergic neurons containing one DA synthesis enzyme in cooperation, is known to have an inhibitory effect on prolactin secretion. Deterioration of this inhibitory control leads to an increase in prolactin concentration in the blood and to the development of hyperprolactinemia syndrome. In a rat model of hyperprolactinemia induced by administration of a neurotoxin causing degeneration of dopaminergic and noradrenergic neurons, the level of DA first decreases, leading to an increase in prolactin level (decompensation stage), while later both levels are restored to normal (compensation stage). However, the mechanism of such compensation is still not clear. The aim of the present study was to analyze whether the increase in cooperative synthesis of DA by monoenzymatic neurons during hyperprolactinemia is a manifestation of a compensatory mechanism representing a particular case of neuroplasticity. The level of cooperative synthesis in the hyperprolactinemia model and in the control was estimated as the level of synthesis of DA and L-dihydroxyphenylalanine (L-DOPA) - an intermediate product of DA synthesis, when L-DOPA transfer from neurons containing tyrosine hydroxylase into neurons containing aromatic L-amino acid decarboxylase is inhibited. The level of DA synthesis during the decompensation stage was not changed, while during the compensation stage it was lower than the control. Along with a reduction in DA level, during the compensation stage an increase in the extracellular L-DOPA level in the medium was detected. Thus, the compensation of DA deficiency after degeneration of dopaminergic neurons in the mediobasal hypothalamus is due to the increase in cooperative synthesis of DA by monoenzymatic neurons containing one of the complementary enzymes of the DA synthesis pathway.
[Mh] Términos MeSH primario: Neuronas Adrenérgicas/metabolismo
Dopamina/biosíntesis
Neuronas Dopaminérgicas/metabolismo
Hipocampo/metabolismo
Hiperprolactinemia/metabolismo
[Mh] Términos MeSH secundario: Neuronas Adrenérgicas/patología
Animales
Modelos Animales de Enfermedad
Neuronas Dopaminérgicas/patología
Hipocampo/patología
Hiperprolactinemia/patología
Levodopa/biosíntesis
Masculino
Ratas
Ratas Wistar
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
46627O600J (Levodopa); VTD58H1Z2X (Dopamine)
[Em] Mes de ingreso:1703
[Cu] Fecha actualización por clase:170322
[Lr] Fecha última revisión:170322
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170322
[St] Status:MEDLINE
[do] DOI:10.1134/S0006297917030154



página 1 de 301 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud